Article
Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer.
Cancer genetics - 1 Aug 2022
Seto Katsutoshi, Shimizu Junichi, Masago Katsuhiro, Araki Mitsugu, Katayama Ryohei, Sagae Yukari, Fujita Shiro, Horio Yoshitsugu, Sasaki Eiichi, Kuroda Hiroaki, Okubo Kenichi, Okuno Yasushi, Hida Toyoaki
Abstract excerpt
PURPOSE: The present study clarified the sensitivity of the BRAF tyrosine kinase inhibitor mechanism in patients with BRAF compound mutation and predicted the sensitivity using molecular dynamics simulation. METHODS: We examined 16 BRAF tumors with p.V600E-positive non-small-cell lung cancer. RESULTS: One patient (6.2%) had a BRAF p.V600E and p.K601_W604 compound mutation with a good clinical response to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.